title: The role of self-monitoring of blood glucose in patients treated with SGLT-2 inhibitors: a European expert recommendation.
abstract: The role for the novel treatment approach of sodium-glucose cotransporter-2 (SGLT-2) in type 2 diabetes is increasing. Structured self-monitoring of blood glucose (SMBG), based on a less intensive and a more intensive scheme, may contribute to an optimization of SGLT-2 inhibitor based treatment. The current expert recommendation suggests individualized approaches of SMBG, using simple and clinically applicable schemes. Potential benefits of SMBG in SGLT-2 inhibitor based treatment approaches are early assessment of treatment success or failure, timely modification of treatment, detection of hypoglycemic episodes, assessment of glucose excursions, and support of diabetes management and education. The length and frequency of SMBG should depend on the clinical setting and the quality of metabolic control.
authors.affiliation: Forschergruppe Diabetes e.V., Helmholtz Center, Munich, Germany oliver.schnell@lrz.uni-muenchen.de.
authors.forename: Oliver
authors.initials: O
authors.lastname: Schnell
authors.affiliation: Diabetes Centrum Saar, Saarlouis, Germany.
authors.forename: Hasan
authors.initials: H
authors.lastname: Alawi
authors.affiliation: University Children's Hospital, Ljubljana, Slovenia.
authors.forename: Tadej
authors.initials: T
authors.lastname: Battelino
authors.affiliation: Insititut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Barcelona, Spain.
authors.forename: Antonio
authors.initials: A
authors.lastname: Ceriello
authors.affiliation: Bern University Hospital, Bern, Switzerland.
authors.forename: Peter
authors.initials: P
authors.lastname: Diem
authors.affiliation: Foundation of European Nurses in Diabetes (FEND), London, UK.
authors.forename: Anne-Marie
authors.initials: AM
authors.lastname: Felton
authors.affiliation: University of Eastern Finland, Joensuu, Finland.
authors.forename: Kari
authors.initials: K
authors.lastname: Harno
authors.affiliation: Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey.
authors.forename: Ilhan
authors.initials: I
authors.lastname: Satman
authors.affiliation: Hôpital du Bocage, Dijon, France.
authors.forename: Bruno
authors.initials: B
authors.lastname: Vergès
mesh_terms: D015190:Blood Glucose Self-Monitoring; D003920:Diabetes Mellitus / Q000097:blood* / Q000188:drug therapy*; D006801:Humans; D007003:Hypoglycemia / Q000097:blood / Q000139:chemically induced; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D010353:Patient Education as Topic; D057285:Precision Medicine; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D016896:Treatment Outcome
chemical_list: D007004:Hypoglycemic Agents; C089180:SLC5A2 protein, human; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors
keywords: SGLT-2 inhibitors; SMBG; hypoglycemia; self-monitoring of blood glucose; type 2 diabetes